Chile boosts child cancer care, lacks technology:
This article was originally published in Clinica
Chile accepts that it lacks the equipment, consumables and sophisticated imaging and other testing necessary to improve the delivery of its integrated paediatric cancer care programme. This assessment is contained in a new manual on early detection of childhood cancers in the primary care setting, published last week by the health ministry. It says that "although the programme is complete and there are no waiting lists, it is not perfect". Cancer is the second-largest cause of death among Chile's 5-15 year olds (totalling some 4.3 million in 2001), at a rate of 3.4 cases for every 100,000. The programme was established in 1999.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.